Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Survivors who stop taking aspirin increase risk of another stroke

03.02.2005


American Stroke Association meeting report



Stroke survivors who stopped taking their prescribed daily aspirin tripled their risk of having another stroke within the month, according to research presented today at the American Stroke Association’s International Stroke Conference 2005. "This is the first controlled retrospective study to investigate the potential risk of suffering ischemic stroke shortly after discontinuing aspirin," said Patrik Michel, M.D., co-author of the study and director of the acute stroke unit at Lausanne University Hospital in Lausanne, Switzerland.

The results confirm and extend previous observations in stroke survivors who stopped taking aspirin. Aspirin is the most often prescribed medication to prevent a recurrent stroke or heart attack, Michel said. This study reinforces the importance of compliance with aspirin therapy in patients with symptomatic atherosclerosis, including previous stroke. Patients and physicians should be aware of a possible increased risk of stroke when aspirin is stopped.


Researchers selected 309 patients who had a stroke or transient ischemic attack (TIA) and were on long-term aspirin therapy for secondary prevention of heart attack and stroke. They matched these patients with 309 control patients who had a stroke or TIA more than six months before and were also taking long-term aspirin therapy.

The average age of the entire study population was 71 years, and 62 percent were men. In each group about 69 percent had hypertension, 20 percent had diabetes, and 14 percent were smokers. In the study group, 52 percent had dyslipidemia compared to 58 percent in the control group (not statistically significant). In the study group, 36 percent had coronary heart disease compared to 18 percent in the control group (a statistically significant difference). Also, a similar number of patients in both groups were taking either a 100 mg or 300 mg dosage of aspirin.

Researchers found that 13 patients in the stroke group had discontinued aspirin within four weeks before their stroke, while only four patients did in the control group. Therefore, patients with stroke or TIA were 3.25 times more likely to have interrupted their aspirin than patients with similar risk factors but no new stroke or TIA. Seventy-seven percent of the ischemic strokes related to aspirin discontinuation occurred in the first eight days after aspirin was stopped; the other 23 percent occurred from day nine to 30.

"Although the absolute risk of suffering a substantial stroke during a short period of aspirin discontinuation is probably not very high, this difference is meaningful, and patients and physicians should be informed about this potential risk," Michel said.

About one-third of patients in the study group discontinued aspirin themselves because of minor bleeding or lack of compliance. In about two-thirds of patients, physicians had ordered aspirin discontinuation for minor bleeding or minor surgical procedures.

The current literature suggests that many diagnostic or surgical procedures, such as cataract surgery or dermatological procedures, may be safely performed while the patient is taking low-dose aspirin.

Michel said a prospective, controlled, randomized trial should be conducted to prove exactly what the stroke risk is from discontinuing aspirin use. He said that such a trial should be a cooperative effort between neurologists, general practitioners, and sub-specialists doing diagnostic and surgical procedures for which aspirin is often discontinued.

Lead author on the study is Alexandre Maulaz, M.D. Other co-authors are Daniel Bezerra, M.D.; Bartolomeij Piechowski-Joywiak, M.D.; and Julien Bogousslavsky, M.D.

Carole Bullock | EurekAlert!
Further information:
http://www.heart.org

More articles from Health and Medicine:

nachricht Electrical 'switch' in brain's capillary network monitors activity and controls blood flow
27.03.2017 | Larner College of Medicine at the University of Vermont

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Northern oceans pumped CO2 into the atmosphere

27.03.2017 | Earth Sciences

Fingerprint' technique spots frog populations at risk from pollution

27.03.2017 | Life Sciences

Big data approach to predict protein structure

27.03.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>